Literature DB >> 24669181

Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options.

Jack McCain.   

Abstract

A survival benefit has been demonstrated or is under investigation as the primary outcome among certain recently approved agents and investigational agents for men with metastatic castration-resistant prostate cancer that has spread to bone.

Entities:  

Year:  2014        PMID： 24669181      PMCID： PMC3956387     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  26 in total

Review 1.  Mechanisms of bone metastasis.

Authors:  G David Roodman
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

2.  Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

Authors:  David I Quinn; Catherine M Tangen; Maha Hussain; Primo N Lara; Amir Goldkorn; Carol M Moinpour; Mark G Garzotto; Philip C Mack; Michael A Carducci; J Paul Monk; Przemyslaw W Twardowski; Peter J Van Veldhuizen; Neeraj Agarwal; Celestia S Higano; Nicholas J Vogelzang; Ian M Thompson
Journal:  Lancet Oncol       Date:  2013-07-17       Impact factor: 41.316

3.  NCCN welcomes 2 new member institutions.

Authors:  Robert W Carlson
Journal:  J Natl Compr Canc Netw       Date:  2013-04-01       Impact factor: 11.908

Review 4.  Emerging therapies to prevent skeletal morbidity in men with prostate cancer.

Authors:  Philip J Saylor; Richard J Lee; Matthew R Smith
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

5.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

6.  Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.

Authors:  Joel B Nelson; Karim Fizazi; Kurt Miller; Celestia Higano; Judd W Moul; Hideyuki Akaza; Thomas Morris; Stuart McIntosh; Kristine Pemberton; Martin Gleave
Journal:  Cancer       Date:  2012-07-11       Impact factor: 6.860

7.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

Review 10.  Pathogenesis of osteoblastic bone metastases from prostate cancer.

Authors:  Toni Ibrahim; Emanuela Flamini; Laura Mercatali; Emanuele Sacanna; Patrizia Serra; Dino Amadori
Journal:  Cancer       Date:  2010-03-15       Impact factor: 6.860
View more
  7 in total

1.  Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.

Authors:  Caroline S Clarke; Rachael M Hunter; Andrea Gabrio; Christopher D Brawley; Fiona C Ingleby; David P Dearnaley; David Matheson; Gerhardt Attard; Hannah L Rush; Rob J Jones; William Cross; Chris Parker; J Martin Russell; Robin Millman; Silke Gillessen; Zafar Malik; Jason F Lester; James Wylie; Noel W Clarke; Mahesh K B Parmar; Matthew R Sydes; Nicholas D James
Journal:  PLoS One       Date:  2022-06-02       Impact factor: 3.752

2.  Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies.

Authors:  Antoine Thiery-Vuillemin; Karim Fizazi; Oliver Sartor; Stéphane Oudard; Denise Bury; Ayse Ozatilgan; Elizabeth M Poole; Mario Eisenberger; Johann de Bono
Journal:  Oncologist       Date:  2021-05-21

Review 3.  The gut microbiota can be a potential regulator and treatment target of bone metastasis.

Authors:  Kelly F Contino; Hariom Yadav; Yusuke Shiozawa
Journal:  Biochem Pharmacol       Date:  2022-01-15       Impact factor: 5.858

Review 4.  Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.

Authors:  Alexandra Vander Ark; Jingchen Cao; Xiaohong Li
Journal:  Front Oncol       Date:  2018-05-24       Impact factor: 6.244

5.  Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.

Authors:  Beth S Woods; Eleftherios Sideris; Matthew R Sydes; Melissa R Gannon; Mahesh K B Parmar; Mymoona Alzouebi; Gerhardt Attard; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir R Chakraborti; Audrey Cook; William R Cross; David P Dearnaley; Joanna Gale; Stephanie Gibbs; John D Graham; Robert Hughes; Rob J Jones; Robert Laing; Malcolm D Mason; David Matheson; Duncan B McLaren; Robin Millman; Joe M O'Sullivan; Omi Parikh; Christopher C Parker; Clive Peedell; Andrew Protheroe; Alastair W S Ritchie; Angus Robinson; J Martin Russell; Matthew S Simms; Narayanan N Srihari; Rajaguru Srinivasan; John N Staffurth; Santhanam Sundar; George N Thalmann; Shaun Tolan; Anna T H Tran; David Tsang; John Wagstaff; Nicholas D James; Mark J Sculpher
Journal:  Eur Urol Oncol       Date:  2018-09-14

Review 6.  Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.

Authors:  Chirayu M Patel; Thaddeus J Wadas; Yusuke Shiozawa
Journal:  Molecules       Date:  2021-04-09       Impact factor: 4.411

7.  The impacts of exosomes on bone metastatic progression and their potential clinical utility.

Authors:  Jenna Ollodart; Kelly F Contino; Gagan Deep; Yusuke Shiozawa
Journal:  Bone Rep       Date:  2022-07-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.